Pneumococcal conjugate vaccine: do not routinely vaccinate adults aged 65 years and older.

A randomised placebo-controlled trial of 13-valent pneumococcal conjugate vaccine was conducted in about 84 500 adults aged 65 years and older, with no particular risk factors. Four years on average after vaccination, there was no reduction in either mortality or the overall incidence of community-acquired pneumonia. It was necessary to vaccinate about 1000 individuals in order to prevent one case of vaccine-type pneumococcal pneumonia during the 4-year follow-up period.